Keay Nakae
Stock Analyst at Chardan Capital
(4.22)
# 416
Out of 5,156 analysts
230
Total ratings
43.53%
Success rate
18.86%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $17.06 | +122.74% | 15 | Mar 3, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $475 → $425 | $318.65 | +33.38% | 15 | Feb 13, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $2.39 | +109.21% | 6 | Feb 12, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $55.95 | +78.73% | 7 | Jan 29, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $7 → $15 | $12.30 | +21.95% | 5 | Jan 29, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.77 | +193.50% | 23 | Jan 8, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 → $80 | $58.61 | +36.50% | 23 | Jan 7, 2026 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Buy | $40 | $3.01 | +1,227.71% | 1 | Jan 5, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $24 → $35 | $37.52 | -6.72% | 1 | Jan 5, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $30 | $21.29 | +40.91% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $3.78 | +217.88% | 19 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.66 | +7.30% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 | $4.59 | +336.21% | 13 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.88 | +113.33% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $6.17 | +467.72% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $9.26 | -35.21% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $2.99 | +101.01% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.51 | +1,461.28% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $15.13 | -60.34% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $7.20 | +5,177.78% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.19 | +571.55% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.09 | +144.49% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $28.21 | +210.17% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.63 | +697.55% | 3 | Feb 9, 2021 |
Dyne Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $38
Current: $17.06
Upside: +122.74%
Alnylam Pharmaceuticals
Feb 13, 2026
Maintains: Buy
Price Target: $475 → $425
Current: $318.65
Upside: +33.38%
iBio, Inc.
Feb 12, 2026
Maintains: Buy
Price Target: $5
Current: $2.39
Upside: +109.21%
Monopar Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $100
Current: $55.95
Upside: +78.73%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $12.30
Upside: +21.95%
Coya Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $14
Current: $4.77
Upside: +193.50%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $58.61
Upside: +36.50%
Reviva Pharmaceuticals Holdings
Jan 5, 2026
Maintains: Buy
Price Target: $40
Current: $3.01
Upside: +1,227.71%
Stoke Therapeutics
Jan 5, 2026
Maintains: Buy
Price Target: $24 → $35
Current: $37.52
Upside: -6.72%
Alto Neuroscience
Jan 5, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $21.29
Upside: +40.91%
Dec 18, 2025
Maintains: Buy
Price Target: $12
Current: $3.78
Upside: +217.88%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.66
Upside: +7.30%
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.59
Upside: +336.21%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.88
Upside: +113.33%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.17
Upside: +467.72%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $9.26
Upside: -35.21%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $2.99
Upside: +101.01%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.51
Upside: +1,461.28%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $15.13
Upside: -60.34%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $7.20
Upside: +5,177.78%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.19
Upside: +571.55%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.09
Upside: +144.49%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $28.21
Upside: +210.17%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.63
Upside: +697.55%